That the Union Health Ministry takes critical decisions affecting a large number of people without any scientific basis does not portend well for public health in India. Neither the ban imposed on the oral anti-diabetes drug pioglitazone on June 18 nor its revocation a month later with a requirement that the medicine be sold with … Continue reading Editorial: Let the science decide on plioglitazone
Sitaglipitin
Drugs board wants ban on Pioglitazone diabetes drug revoked
The Drugs Technical Advisory Board (DTAB) on Friday recommended revoking the ban on pioglitazone — an oral anti-diabetic drug which was banned on June 18. But the DTAB, which was kept in the dark when the decision to ban was taken, has also recommended that the medicine be sold with a boxed warning (that the … Continue reading Drugs board wants ban on Pioglitazone diabetes drug revoked
Science Chronicle 